DE69332735D1 - Verwendung von Benzothiophene zur Behandlung von Hypercholesterolämie - Google Patents

Verwendung von Benzothiophene zur Behandlung von Hypercholesterolämie

Info

Publication number
DE69332735D1
DE69332735D1 DE69332735T DE69332735T DE69332735D1 DE 69332735 D1 DE69332735 D1 DE 69332735D1 DE 69332735 T DE69332735 T DE 69332735T DE 69332735 T DE69332735 T DE 69332735T DE 69332735 D1 DE69332735 D1 DE 69332735D1
Authority
DE
Germany
Prior art keywords
alkanoyloxy
substituted
unsubstituted
cycloalkanoyloxy
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332735T
Other languages
English (en)
Other versions
DE69332735T2 (de
Inventor
Larry John Black
Henry Uhlman Bryant
George Joseph Cullinan
Raymond Francis Kauffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69332735D1 publication Critical patent/DE69332735D1/de
Application granted granted Critical
Publication of DE69332735T2 publication Critical patent/DE69332735T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE69332735T 1992-12-22 1993-12-22 Verwendung von Benzothiophene zur Behandlung von Hypercholesterolämie Expired - Fee Related DE69332735T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99522292A 1992-12-22 1992-12-22

Publications (2)

Publication Number Publication Date
DE69332735D1 true DE69332735D1 (de) 2003-04-10
DE69332735T2 DE69332735T2 (de) 2003-10-23

Family

ID=25541537

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332735T Expired - Fee Related DE69332735T2 (de) 1992-12-22 1993-12-22 Verwendung von Benzothiophene zur Behandlung von Hypercholesterolämie

Country Status (28)

Country Link
US (1) US5464845A (de)
EP (2) EP1238667A3 (de)
JP (1) JP3197129B2 (de)
KR (1) KR100278946B1 (de)
CN (1) CN1043608C (de)
AT (1) ATE233559T1 (de)
AU (1) AU669235B2 (de)
BG (1) BG61524B1 (de)
BR (1) BR9305182A (de)
CA (1) CA2112017C (de)
CZ (1) CZ283863B6 (de)
DE (1) DE69332735T2 (de)
DK (1) DK0605193T3 (de)
ES (1) ES2193142T3 (de)
HU (1) HU223342B1 (de)
IL (1) IL108042A (de)
MY (1) MY109345A (de)
NO (1) NO304924B1 (de)
NZ (1) NZ250486A (de)
PH (1) PH30430A (de)
PL (1) PL177349B1 (de)
RO (1) RO113806B1 (de)
RU (1) RU2123335C1 (de)
SG (1) SG52696A1 (de)
SK (1) SK279271B6 (de)
TW (1) TW383306B (de)
YU (1) YU48918B (de)
ZA (1) ZA939427B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
IL112034A (en) * 1993-12-21 1999-03-12 Lilly Co Eli Use of raloxifene and related compounds in the preparation of medicaments useful for the inhibition of ldl oxidation and atherosclerosis
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
WO1996012489A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
WO1996032937A1 (en) * 1995-04-21 1996-10-24 Eli Lilly And Company Benzothiophenes with novel basic side chains
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
EP0801066A1 (de) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterozyklisch substituierte Benzothiophene und pharmazeutische Zusammensetzungen
AU5258696A (en) * 1996-03-19 1997-10-10 Eli Lilly And Company Synthesis of 3-{4-(2-aminoethoxy)-benzoyl}-2-aryl-6-hydroxy-benzo{b}thiop henes
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
WO1998048787A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES
AU7165398A (en) * 1997-04-30 1998-11-24 Eli Lilly And Company A regioselective alkylation process for preparing substituted benzo{b}thiophenes
KR20010020378A (ko) * 1997-04-30 2001-03-15 피터 지. 스트링거 벤조티오펜의 제조 방법
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
CA2231013A1 (en) * 1997-04-30 1998-10-30 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
AU7261498A (en) * 1997-04-30 1998-11-24 Eli Lilly And Company Intermediates and processes for preparing benzo{b}thiophenes
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6087378A (en) * 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
BR0016560A (pt) 1999-12-22 2002-09-10 Pfizer Prod Inc Agonistas seletivos do receptor ep4 no tratamento da osteoporose
ES2274854T3 (es) * 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
BRPI0417621A (pt) * 2003-12-17 2007-04-10 Pfizer Prod Inc terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
CA2694642C (en) 2007-07-27 2017-05-16 Container Stuffers, Llc Cargo loader
CN101669557B (zh) * 2009-08-20 2012-07-25 杭州六易科技有限公司 一种清热解毒凉茶的制作方法
JPWO2016021706A1 (ja) * 2014-08-08 2017-05-25 カズマパートナーズ株式会社 縮合複素環化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene

Also Published As

Publication number Publication date
BR9305182A (pt) 1994-08-16
BG98317A (en) 1995-02-28
NO934740D0 (no) 1993-12-21
HU223342B1 (hu) 2004-06-28
YU48918B (sh) 2002-11-15
ZA939427B (en) 1995-06-15
NO934740L (no) 1994-06-23
EP0605193B1 (de) 2003-03-05
ATE233559T1 (de) 2003-03-15
JP3197129B2 (ja) 2001-08-13
CZ279093A3 (en) 1994-07-13
CZ283863B6 (cs) 1998-06-17
PL177349B1 (pl) 1999-10-29
IL108042A0 (en) 1994-04-12
IL108042A (en) 1998-01-04
DK0605193T3 (da) 2003-03-31
EP1238667A2 (de) 2002-09-11
HUT69686A (en) 1995-09-28
BG61524B1 (bg) 1997-11-28
NO304924B1 (no) 1999-03-08
CN1094042A (zh) 1994-10-26
HU9303676D0 (en) 1994-04-28
YU79893A (sh) 1997-05-28
DE69332735T2 (de) 2003-10-23
RO113806B1 (ro) 1998-11-30
KR940013501A (ko) 1994-07-15
AU669235B2 (en) 1996-05-30
SK279271B6 (sk) 1998-08-05
AU5257893A (en) 1994-07-07
KR100278946B1 (ko) 2001-01-15
EP0605193A1 (de) 1994-07-06
SG52696A1 (en) 1998-09-28
JPH06234632A (ja) 1994-08-23
PL301579A1 (en) 1994-06-27
RU2123335C1 (ru) 1998-12-20
MY109345A (en) 1997-01-31
SK142193A3 (en) 1995-01-12
US5464845A (en) 1995-11-07
CA2112017C (en) 2005-06-14
TW383306B (en) 2000-03-01
NZ250486A (en) 1997-06-24
PH30430A (en) 1997-05-09
ES2193142T3 (es) 2003-11-01
CN1043608C (zh) 1999-06-16
CA2112017A1 (en) 1994-06-23
EP1238667A3 (de) 2003-12-10

Similar Documents

Publication Publication Date Title
DE69332735T2 (de) Verwendung von Benzothiophene zur Behandlung von Hypercholesterolämie
DE69513708T2 (de) Verwendung von 3,4-diphenyl chroman Derivaten zur Herstellung eines Medikaments zur Absinkung des Cholesterolspiegels
AU591780B2 (en) Benzo{b}thiophene- and benzo{b}furancarboxamide derivatives their preparation, and pharmaceutical compositions containing them
DE69505968D1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
ATE25682T1 (de) Indol-3-carboxamid-derivate.
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
ATE220323T1 (de) Methode zur behandlung von resistenten neoplasmen
ATE285238T1 (de) Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl- phenol derivaten
NZ197809A (en) 5-(3-(azacycloalk-1-yl)propionyl)-10,11-dihydro-5h-dibenzo-(b,e)(1,4)diazepin-11-ones
ATE63541T1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
CA1246583A (en) 4-ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND THEIR DERIVATIVES
NZ296285A (en) Inhibiting physiological conditions associated with bradykinin using a benzothiophene such as raloxifene
YU6996A (sh) Upotreba benzotiofena za dobijanje leka
NO20000750D0 (no) Fremgangsmåte for å redusere blodplatetall
ATE144900T1 (de) Verwendung von xanthinderivaten gegen magengeschwüre
JPS5430166A (en) 2-aminomethyl-5-phenyloxazoles and their pharmaceutically acceptable acid salts

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee